The Office of Congressional Ethics is examining New York Rep. Chris Collins' role in attracting U.S. investors to an Australian biotech company in which he is the largest shareholder, The Buffalo News reported Tuesday.
The story cited unnamed sources who told the newspaper that the office began sending letters to investors seeking information about a month ago. Legally, they are not required to provide it or submit to interviews.
